Clinical trials: Suicide, Ideation
Suicide, Mental Health Disorder
Optimizing a Just-in-time Adaptive Intervention for Suicide Safety Planning in Adolescents
Despite efforts to prevent suicide, US rates are climbing, and suicide is the second leading cause of death amongst youth. Digital tools, especially personal smartphones, are promising avenues to address these issues and can be…
- Conditions
- Suicide, Mental Health Disorder, Anhedonia
- Trial name
- NCT06665620
- Testing
- ViraBrite nudges
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Ksana Health
Suicide
CAMS-RAS: for Suicide Prevention
This Phase I feasibility study endeavors to create a prototype of a tool to determine its feasibility with suicidal patients in emergency departments (EDs). This is not a clinical trial.
- Trial name
- CAMS-RAS (NCT03072875)
- Testing
- CAMS-RAS
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Evidence-Based Practice Institute, Seattle, WA
Suicide, Mental Health Disorder
A Just-in-time Adaptive Intervention for Suicide Safety Planning in Adolescents
Despite efforts to prevent suicide, US rates are climbing, and suicide is the second leading cause of death amongst youth. Digital tools, especially personal smartphones, are promising avenues to address these issues and can be…
- Conditions
- Suicide, Mental Health Disorder, Anhedonia
- Trial name
- ViraSafeRCT (NCT07348666)
- Testing
- ViraSafe: Treatment pushes, BRITE
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Ksana Health
Depressive Disorder, Major
54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide
The purpose of this study is to evaluate the efficacy of intranasal esketamine 84 milligram (mg) compared with intranasal placebo in addition to comprehensive standard of care in reducing the symptoms of Major Depressive Disorder…
- Trial name
- Aspire II (NCT03097133)
- Testing
- Esketamine, Standard of Care
- Where
- 61 sites in United States, Argentina and 10 more
- Volunteers
- 230 people
- Sponsor
- Janssen Research & Development, LLC
Bipolar Depression, Suicidal Ideation
NRX100 vs. Placebo for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Bipolar Depression
NMDA antagonist drugs have increasingly been demonstrated to reduce symptoms of depression and suicidal ideation. NeuroRx has developed a sequential therapy consisting of IV NRX-100 (ketamine HCL) for rapid stabilization of…
- Trial name
- SevereBD (NCT03396601)
- Testing
- Ketamine Hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- NeuroRx, Inc.
Suicide, Attempted, Suicidal Ideation
A Study to Evaluate the Safety and Effectiveness of a Digital Therapeutic
The primary objective of this study is to assess the effectiveness of a digital intervention in reducing suicide attempts.
- Trial name
- NCT05144685
- Testing
- OTX-202, OTX-000, Treatment as Usual
- Where
- 6 sites in United States
- Volunteers
- 356 people, healthy volunteers welcome
- Sponsor
- Oui Therapeutics, Inc.
Suicide Ideation, Suicidal Intention
Classification and Assessment of Mental Health Performance Using Schematics
This is an open enrollment study to collect data for the optimization of smartphone-based algorithms for the early detection of mental health and suicidal risk in a student population.
- Conditions
- Suicide Ideation, Suicidal Intention, Suicide and Depression
- Trial name
- CAMPUS (NCT04275908)
- Testing
- MHSAFE app
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Clarigent Health
Bipolar Depression, Suicidal Ideation and Behavior
NRX-101 for Bipolar Depression With Subacute Suicidal Ideation
NMDA antagonist drugs have shown to reduce symptoms of depression and suicidal ideation. NeuroRx has developed NRX-101 (fixed dose combination of D-cycloserine and lurasidone) for oral use in the treatment of bipolar depression…
- Trial name
- NCT03395392
- Testing
- NRX-101, Lurasidone HCl
- Where
- 14 sites in United States
- Volunteers
- 74 people
- Sponsor
- NeuroRx, Inc.
Bipolar Depression, Suicidal Ideation
NRX101 Glx Biomarker Validation Study
Subnormal level of Glutamate+Glutamine (Glx) in the Anterior Cingulate Cortex (ACC) of the brain has been associated with depression and PTSD.
- Trial name
- NRX-GLX (NCT03402152)
- Testing
- NRX-101, Lurasidone HCl
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- NeuroRx, Inc.
Suicide
CAMS Relational Agent System (CAMS-RAS) for Suicide Prevention
This Phase II study is a continuation of the Phase I feasibility study where the investigators fully met and exceeded project aims to design, build, and test the usability and acceptability of an avatar-based system, Jaspr Health…
- Trial name
- V-CAMS (NCT03584386)
- Testing
- Jaspr, Jaspr-at-Home (JAH)
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- Evidence-Based Practice Institute, Seattle, WA
Major Depressive Disorder, Major Depressive Episode
SAINT for MDD in an Inpatient Setting Follow-on
Randomized, multi-site, sham-controlled, double-blinded study
- Conditions
- Major Depressive Disorder, Major Depressive Episode, Suicidal Ideation
- Trial name
- NCT06462820
- Testing
- Active SAINT Stimulation
- Where
- 4 sites in United States
- Volunteers
- 2 people
- Sponsor
- Magnus Medical
Depressive Disorder
Study to Evaluate the Safety and Efficacy of PEER Interactive Versus Treatment as Usual in Subjects With a Primary Diagnosis of Depression
This is a prospective, multicenter, randomized, double-blind, controlled study to evaluate the effectiveness of PEER Interactive to inform treatment in subjects with a primary diagnosis of depression with comorbidity of…
- Trial name
- NCT01794559
- Testing
- PEER Interactive Report
- Where
- 2 sites in United States
- Volunteers
- 1,922 people
- Sponsor
- MYnd Analytics
Suicide, Attempted, Suicidal Ideation
Feasibility Study of a Software Application for Patients Hospitalized After Suicidal Ideation or Suicide Attempts
The primary objective of this feasibility study is to assess the feasibility, and usability of a software application to deliver targeted interactive exercises to patients recently hospitalized for suicidal ideation or suicide…
- Trial name
- NCT04295382
- Testing
- Software Application
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Oui Therapeutics, Inc.
Suicide, Suicide, Attempted
Drivers of Suicide Mobile App Study
The central purpose of this project is to evaluate and facilitate access to evidence-based best practices for individuals struggling with suicidal ideation and co-occurring behavioral problems, including alcohol misuse, and…
- Conditions
- Suicide, Suicide, Attempted, Suicidal Ideation, Alcohol Use Disorder
- Trial name
- NCT05427734
- Testing
- WisePath for Adults, Active-Control app + electronic wellness resources brochure
- Where
- United States
- Volunteers
- 127 people
- Sponsor
- Evidence-Based Practice Institute, Seattle, WA
Suicidality
A Study to Assess the Validation and Mapping of the Suicide Ideation and Behavior Assessment
The main purpose of this cross-sectional study is to generate data to support the psychometric properties of the Suicide Ideation and Behavior Assessment Tool (SIBAT) and validate its use in participants at imminent risk of…
- Trial name
- NCT03085108
- Testing
- No Intervention
- Where
- 4 sites in United States
- Volunteers
- 130 people
- Sponsor
- Janssen Scientific Affairs, LLC
Depressive Disorder, Major
54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide
The purpose of the study is to evaluate the efficacy of intranasal esketamine 84 milligram (mg) compared with intranasal placebo in addition to comprehensive standard of care in reducing the symptoms of Major Depressive Disorder…
- Trial name
- Aspire I (NCT03039192)
- Testing
- Esketamine, Standard of Care
- Where
- 56 sites in United States, Bulgaria and 9 more
- Volunteers
- 226 people
- Sponsor
- Janssen Research & Development, LLC
Suicidal Ideation
Correlation of Campbell Score With Suicidal Ideation
The Campbell Score is a blood based means of assessing molecules believed to be associated with suicidal ideation and in some cases successful suicide.
- Trial name
- NCT04606875
- Testing
- Campbell Score
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Therapeutic Solutions International
Bipolar Depression, Suicidal Ideas
Sequential Therapy for the Treatment of Severe Bipolar Depression.
NeuroRx is developing NRX-101, a fixed-dose combination oral capsule composed of d-cycloserine (DCS) and lurasidone for the maintenance of remission from Severe Bipolar Depression with Acute Suicidal Ideation (C-SSRS level 4 or…
- Conditions
- Bipolar Depression, Suicidal Ideas, Suicidal Ideation, Suicide, Attempted
- Trial name
- STABIL-B (NCT02974010)
- Testing
- NRX-101 Oral Capsule, Lurasidone Oral Capsule, Ketamine Intravenous Infusion
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- NeuroRx, Inc.
Major Depressive Disorder
A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for Suicide
The purpose of this study is to evaluate the efficacy of intranasal esketamine 84 milligram (mg) compared with intranasal placebo along with standard care treatment, in reducing the symptoms of major depressive disorder (MDD) (an…
- Trial name
- NCT02133001
- Testing
- Esketamine
- Where
- 14 sites in United States
- Volunteers
- 68 people
- Sponsor
- Janssen Research & Development, LLC
Psoriasis
Post-Marketing Surveillance Study of OTEZLA
To evaluate the safety and efficacy of OTEZLA in actual clinical settings of use in patients with Psoriasis vulgaris that is with an inadequate response to topical therapies and Psoriasis arthropathica 1.
- Trial name
- NCT03284879
- Where
- Japan
- Volunteers
- 1,086 people
- Sponsor
- Amgen